Alexander Roth

Summary

Affiliation: University of Duisburg-Essen
Country: Germany

Publications

  1. ncbi Imetelstat (GRN163L)--telomerase-based cancer therapy
    Alexander Roth
    Department of Hematology, University Hospital Essen, University of Duisburg Essen, Hufelandstrasse 55, 45122, Essen, Germany
    Recent Results Cancer Res 184:221-34. 2010
  2. ncbi [Paroxysmal nocturnal hemoglobinuria (PNH). Pathogenesis, diagnosis and treatment]
    A Roth
    Klinik für Hämatologie, Universitatsklinikum Essen, Universitat Duisburg Essen
    Dtsch Med Wochenschr 134:404-9. 2009
  3. ncbi Impact of culture conditions on the proliferative lifespan of human T cells in vitro
    A Roth
    Department of Hematology, University Hospital Essen, University of Duisburg Essen, Essen, Germany
    Cytotherapy 9:91-8. 2007
  4. ncbi Short telomeres and high telomerase activity in T-cell prolymphocytic leukemia
    A Roth
    Department of Hematology, University Hospital Essen, University of Duisburg Essen, Essen, Germany
    Leukemia 21:2456-62. 2007
  5. ncbi Dyskeratosis congenita
    Alexander Roth
    Department of Hematology, University Hospital, Essen, Germany
    Br J Haematol 141:412. 2008
  6. ncbi Significantly shorter telomeres in T-cells of patients with ZAP-70+/CD38+ chronic lymphocytic leukaemia
    Alexander Roth
    Department of Haematology, University Hospital, Essen, Germany
    Br J Haematol 143:383-6. 2008
  7. ncbi Telomeres and prognosis in patients with chronic lymphocytic leukaemia
    Ludger Sellmann
    Department of Haematology, University of Duisburg Essen, Essen, Germany
    Int J Hematol 93:74-82. 2011
  8. ncbi Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity
    Holger Nuckel
    Department of Hematology, Medical School, University of Duisburg Essen, Germany
    Eur J Pharmacol 514:217-24. 2005
  9. ncbi Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena
    Alexander Roth
    Department of Hematology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany
    Int J Hematol 93:704-14. 2011
  10. ncbi Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab
    Alexander Roth
    Department of Hematology, West German Cancer Center, University Hospital Essen, Germany
    Eur J Haematol 87:473-9. 2011

Collaborators

Detail Information

Publications10

  1. ncbi Imetelstat (GRN163L)--telomerase-based cancer therapy
    Alexander Roth
    Department of Hematology, University Hospital Essen, University of Duisburg Essen, Hufelandstrasse 55, 45122, Essen, Germany
    Recent Results Cancer Res 184:221-34. 2010
    ..Here, we report on the structure and the mechanism of action of imetelstat as well as about the preclinical and clinical data and future prospects using imetelstat in cancer therapy...
  2. ncbi [Paroxysmal nocturnal hemoglobinuria (PNH). Pathogenesis, diagnosis and treatment]
    A Roth
    Klinik für Hämatologie, Universitatsklinikum Essen, Universitat Duisburg Essen
    Dtsch Med Wochenschr 134:404-9. 2009
    ....
  3. ncbi Impact of culture conditions on the proliferative lifespan of human T cells in vitro
    A Roth
    Department of Hematology, University Hospital Essen, University of Duisburg Essen, Essen, Germany
    Cytotherapy 9:91-8. 2007
    ..To improve T-cell expansion it is of critical importance to understand the effects of culture parameters on telomerase activity and lifespan...
  4. ncbi Short telomeres and high telomerase activity in T-cell prolymphocytic leukemia
    A Roth
    Department of Hematology, University Hospital Essen, University of Duisburg Essen, Essen, Germany
    Leukemia 21:2456-62. 2007
    ..Targeting the short telomeres and telomerase activity in T-PLL seems an attractive strategy for the future treatment of this devastating disease...
  5. ncbi Dyskeratosis congenita
    Alexander Roth
    Department of Hematology, University Hospital, Essen, Germany
    Br J Haematol 141:412. 2008
  6. ncbi Significantly shorter telomeres in T-cells of patients with ZAP-70+/CD38+ chronic lymphocytic leukaemia
    Alexander Roth
    Department of Haematology, University Hospital, Essen, Germany
    Br J Haematol 143:383-6. 2008
    ..This indicated an extensive expansion and a role for T-cells in ZAP-70(+)/CD38(+) CLL patients...
  7. ncbi Telomeres and prognosis in patients with chronic lymphocytic leukaemia
    Ludger Sellmann
    Department of Haematology, University of Duisburg Essen, Essen, Germany
    Int J Hematol 93:74-82. 2011
    ..Short telomeres and high telomerase activity as occurs in some patients with CLL with a worse prognosis might be an ideal target for treatment with telomerase inhibitors...
  8. ncbi Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity
    Holger Nuckel
    Department of Hematology, Medical School, University of Duisburg Essen, Germany
    Eur J Pharmacol 514:217-24. 2005
    ..Alemtuzumab significantly enhances apoptosis in chronic lymphocytic leukemia cells in vitro, especially in combination with a cross-linking anti-Fc-antibody, this effect being mediated by a caspase-dependent pathway...
  9. ncbi Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena
    Alexander Roth
    Department of Hematology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany
    Int J Hematol 93:704-14. 2011
    ..Iron should not be routinely supplemented in PNH patients treated with eculizumab without close monitoring of iron parameters, and iron depletion therapy should be considered in the case of overload...
  10. ncbi Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab
    Alexander Roth
    Department of Hematology, West German Cancer Center, University Hospital Essen, Germany
    Eur J Haematol 87:473-9. 2011
    ....